Serum analysis in patients with temporomandibular disorders: a controlled cross-sectional study in Norway by Staniszewski, Kordian et al.
Research Article
SerumAnalysis inPatientswithTemporomandibularDisorders:A
Controlled Cross-Sectional Study in Norway
Kordian Staniszewski ,1 Henning Lygre,1 Trond Berge,1,2 and Annika Rosén 1,2
1Department of Clinical Dentistry, University of Bergen, Bergen, Norway
2Department of Oral and Maxillofacial Surgery, Haukeland University Hospital, Bergen, Norway
Correspondence should be addressed to Annika Rosén; annika.rosen@uib.no
Received 27 April 2019; Revised 15 August 2019; Accepted 13 September 2019; Published 7 October 2019
Academic Editor: Manfred Harth
Copyright © 2019 Kordian Staniszewski et al. -is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Temporomandibular disorder (TMD) is characterized by pain and dysfunction in the temporomandibular join (TMJ) and the
masticatory apparatus. Associations with autoimmune diseases, inflammatory conditions, and nutrition deficiencies have been
reported in previous studies of TMD patients. To evaluate essential proteins, hormones, electrolytes, and vitamins in serum
from TMD patients, a standard blood sample analysis was performed in 60 TMD patients and 60 healthy controls matched for
age and gender, retrieving 19 different analyses. We found that TMD patients had significantly higher values of hemoglobin
(p � 0.036), cobalamin (p � 0.023), albumin (p � 0.005), parathyroid hormone (PTH) (p � 0.038), and vitamin D (p � 0.005),
and significantly lower values of creatinine (p � 0.006) and potassium (p � 0.011), compared to controls. In the TMD group,
most of the determinants had a wider range, and several subjects, compared to the control group, had values outside the
normal reference area. However, most of the TMD patients and controls had values within normal biological range. Our
findings could not associate any severe systemic disease, malnutrition, or systemic inflammation with the TMD. Results from
our study suggest that serum analyses should neither be used as a biomarker of TMD nor a diagnostic tool for an individual
subject with TMD.
1. Introduction
Temporomandibular disorder (TMD) is characterized by
pain and dysfunction in the masticatory apparatus and the
temporomandibular joint (TMJ). A significant higher
prevalence of comorbidities, such as degenerative arthritis,
gastrointestinal symptoms, fibromyalgia, depression, and
fatigue, has been revealed in this group of patients [1].
Autoimmune diseases and inflammatory conditions have
been associated with TMJ disease (TMJD) in a recent
hospital-based case-control study [2]. Summary from the
Prospective Evaluation and Risk Assessment (OPPERA)
project describes the etiology of TMD as complex and
multifactorial, where pain sensitivity, biopsychosocial ef-
fects, and comorbidity are some of the contributing factors
[3]. -e prevalence of TMD is higher in women, who had a
two-time higher risk in development of TMD compared to
men [4]. In addition, pain intensity has been reported to be
greater in women compared to men [5].
In TMD patients, few studies analyzing health status in
serum have been published previously. Significantly, higher
levels of parathyroid hormone (PTH) have been observed in
TMDpatients compared to a control group [6]. Patients with
TMD as well as TMJD showed high prevalence of nutrition
deficiencies, including iron, ferritin, vitamin D, vitamin C,
vitamin B1, vitamin B6, vitamin B12, and folate [7, 8]. High
levels of C-reactive protein (CRP) have been associated with
inflammation in the TMJ in patients with rheumatoid ar-
thritis (RA) [9]. On the other hand, no difference in levels of
CRP was reported in patients with persistent TMJ pain,
compared to controls [10]. Low levels of vitamin D have
been associated with incidence of chronic pain [11] and
chronic pain-related comorbidities, including sleep depri-
vation and depression [12]. One study revealed a high
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prevalence of vitamin D deficiencies in TMD patients;
however, there were no significant differences in vitamin D
or calcium levels in those patients compared to a control
group [6].
Levels of the current hormones, electrolytes, and vita-
mins can easily be detected by blood sampling. Standardized
serum tests can be used in diagnostics and evaluation of
patient’s health to detect diseases [13]. Laboratory serum
analyses are also useful in revealing inflammation and au-
toimmune diseases and may indicate severity of the disease
[14].
To our knowledge, the present study is the first to reveal
as many as 19 different determinants in serum from TMD
patients at the same time. -e primary aim of the present
study was to evaluate essential proteins, hormones, elec-
trolytes, and vitamins in serum from TMD patients. Our
hypothesis is that TMD patients have significantly different
values of essential proteins, hormones, electrolytes, and
vitamins in serum, compared to a healthy control group, and
this may influence TMD symptoms.
2. Materials and Methods
2.1. Study Design. -e present study was a controlled cross-
sectional study, as part of a multidisciplinary investigation of
TMD patients at Haukeland University Hospital (HUS) in
Bergen, Norway [15]. Six different specialists including two
dental specialists, one anesthesiologist, one psychologist, one
physiotherapist, and one radiologist examined the patients.
Pain-related symptoms and dysfunction (both general and
TMD-related), general health status, psychosocial factors,
previous treatment andmedication, and the duration of pain
and disease were disclosed.
Ethical approval was granted by the Regional Ethical
Review Board South East (2015/930), in accordance with the
Helsinki Declaration (1964). All subjects submitted written
informed consent as a prerequisite for participating in the
study.
2.2.Participants. -e study population consisted of 60 TMD
patients with severe symptoms and long-term pain and 60
healthy controls matched for age and gender. A previous
study regarding stress and HPA axis regulation, involving
the majority of the present study group, has been published
[16]. -e TMD patients were referred by their general
practitioner (GP) to the project from all health regions in
Norway, during the years 2013–15, and were clinically ex-
amined and evaluated consecutively. Patients were included,
examined, and evaluated based on the severity and duration
of symptoms, both for pain and dysfunction and for con-
sequences. -e six specialists at HUS, representing several
disciplines, performed the examination and created an in-
dividual treatment proposal for each patient. -e in-
vestigation included pain intensity and duration, functional
impairment (general and jaw-specific), effect on quality of
life, and presence of extended periods of sick leave. -e
inclusion criterion was long-term TMD-related pain. Fur-
thermore, inclusion was based on the examination; thus,
patients with and without functional impairment were in-
cluded. -e exclusion criteria were non-TMD-related oro-
facial pain, relevant drug dependence problems, and obvious
psychiatric diagnoses. A healthy age- and gender-matched
control group was recruited and examined during 2016.
-e control group consisted of employees and students
from the Department of Clinical Dentistry at the University
of Bergen and was not a part of the study research group;
additionally, there were a few subjects from the general
population in Bergen. -e inclusion criterion was age- and
gender-matched with the patient group. -e exclusion
criteria were TMD symptoms, musculoskeletal pain, and
symptoms in the head and neck area.
2.3. Serum Analyses. A standard blood sample analysis was
conducted at HaukelandUniversity Hospital and analyzed at
the Laboratory for Clinical Biochemistry. -e serum ana-
lyses retrieved 19 different analyses consisting of essential
proteins, hormones, electrolytes, and vitamins. -ose were
hemoglobin (Hb), erythrocyte volume fraction (EVF), mean
corpuscular volume (MCV), homocysteine, transferrin re-
ceptor (TfR), thyroid stimulating hormone (TSH), free
thyroxine (FT4), parathyroid hormone (PTH), cobalamin,
folate, C-reactive protein (CRP), creatinine, estimated glo-
merular filtration rate (GFR), sodium, potassium, calcium,
gamma-glutamyl transferase (GT), albumin, and 25 (OH)
vitamin D3 (vitamin D). CRP levels lower than 1mg/L were
registered as 1mg/L due to limitations in the laboratory.
2.4. Statistical Analyses. Statistical analyses were performed
in STATA. Mean, range, and standard deviation (SD) were
calculated for all variables in both groups. Since our study
matched age and gender between the groups, paired t-tests
were appropriate to calculate p-value of no difference in all
determinants from the serum analyses between the TMD
group compared to the control group and between sub-
groups of women and men in the TMD group compared to
women and men control group. Linear correlations (R) with
associated p-values between CRP and pain parameters and
between vitamin D and pain parameters, as well as between
vitamin D and PTH, were calculated in both groups.
3. Results
3.1. Demographic Data. -e group of 60 TMD patients
consisted of 51 women and 9 men, all affected with severe
TMD symptoms. Mean pain duration in the patient group
was 11 years (ranged 1–40 years). Mean age of the patient
group was 45 years (ranged 20–69 years). Registered di-
agnoses on our clinical examination of the TMD group were
fibromyalgia (n� 8), migraine (n� 12), and chronic fatigue
(n� 4). -e control group was matched for age and gender
and had a mean age of 46 years (ranged 23–71 years). -e
study population is presented in Figure 1.
3.2. SerumAnalyses. Results revealed that TMD patients had
significantly higher values of hemoglobin (p � 0.036),
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cobalamin (p � 0.023), albumin (p � 0.005), parathyroid
hormone (PTH) (p � 0.038), and vitamin D (p � 0.005),
and significantly lower values of creatinine (p � 0.006) and
potassium (p � 0.011), compared to controls (Table 1).
Further, gender-matched analyses of TMD patients and
controls showed that in the TMD patient group only al-
bumin was significantly higher in both women ((p � 0.017)
and men (p � 0.026). In women with TMD, significantly
higher values of hemoglobin (p � 0.045), cobalamin
(p � 0.020), PTH (p � 0.040), and vitamin D (p � 0.002), as
well as significantly lower values of creatinine (p � 0.018)
and potassium (p � 0.002), were observed. In men with
TMD, significantly higher values of TSH (p � 0.040) were
observed (Table 2). Further details of serum levels outside
normal reference values in both groups are presented in
Table 3. Low levels of vitamin D were significantly correlated
(p � 0.002) with high levels of PTH in the control group,
however nonsignificant in the patient group (Figure 2).
3.3. Medications. Regular medications used by the patients
were paracetamol (n� 28), NSAIDs (n� 23, hereunder
celecoxib in one patient), opioids (n� 20, hereunder strong
opioids in 5 patients and weak opioids in 17 patients),
antidepressants (n� 15, hereunder tricyclic antidepressants
in 7 patients and selective antidepressants in 10 patients),
zopiclone (n� 7), clonazepam (n� 3), gabapentinoids (n� 6,
hereunder gabapentin in 4 patients and pregabalin in 2
patients), carbamazepine (n� 1), and topiramate (n� 1).
Serum levels of calcium and creatinine were normal in
patients who used celecoxib, pregabalin, and topiramate and
were within normal reference values. One patient who used
carbamazepine had slightly elevated levels serum TfR
(5.7mg/L) and normal serum levels of serum Hb.
4. Discussion
Based on the results of the present study, we were unable to
associate any severe systemic disease, malnutrition, or sys-
temic inflammation with TMD. We performed nineteen
different, common diagnostic serum analyses determining
essential proteins, hormones, ions, and vitamins, and most
of the TMD patients and controls showed values within
normal biologic range. Medications used by the patients
were not found to have any major impact on serum analyses.
Findings from our study support results from the OPPERA
project, suggesting that TMD is a complex disorder influ-
enced by psychosocial factors and pain sensation rather than
being a state of disease indicated by analyses of serum
compounds [3]. Supporting observations have also been
reported, currently, regarding levels of vitamin D and cal-
cium [6]. Nonsupporting studies have shown a high prev-
alence of malnutrition including deficiencies in vitamin D,
vitamin B, and iron in a population of TMD patients [7], as
well as a high prevalence of low serum vitamin B, folate, and
iron [8].
An unexpected result revealed that the control group had
significantly lower values of vitamin D compared to the
TMD group. In both groups, deficiency in D vitamins was
commonly observed. A high prevalence of vitamin D de-
ficiencies in both TMD patients and healthy controls [6], as
well as healthy individuals [17], has also been reported
previously. Nearly one half of TMD patients in Saudi
population were also reported to have low vitamin D levels,
although there was no control group for comparison [7]. In
nonspecific musculoskeletal persistent pain, vitamin D de-
ficiency was observed in themajority of all patients, implying
that there is a link between chronic pain and vitamin D
deficiency [18]. Prevalence of vitamin D deficiencies has
been observed to be higher in patients with chronic pain [11]
and has also been associated with chronic widespread pain in
a meta-analysis [19]. Vitamin D supplements, in some
studies, have been linked with alleviation of chronic pain
[11]. Vitamin D has also been suggested to have a function in
the maintenance of chronic pain and associated comor-
bidities through hormonal, immunological, and neurolog-
ical influences [12]. In a randomized controlled trial of
fibromyalgia patients, normalization of vitamin D levels was
associated with a decrease in pain intensity measured on a
visual analog scale (VAS) [20]. On the other hand, results
from a meta-analysis failed to prove the effect of vitamin D
supplementation on pain in subjects with chronic muscu-
loskeletal pain [21]. It also appears that vitamin D deficiency
is quite common in the healthy population and varies
throughout the year [17, 22]. -e difference of lower vitamin
D levels in our control group could potentially be explained
by three factors. First is the geographic factor; all subjects in
the control group lived in Bergen, where the number of
hours of sun per year is very low, while the TMD patients
were from all over the country of Norway. -e second factor
is that TMD patients probably consult with their GP more
often and get their nutritional serum levels analyzed more
often compared to the healthy individuals.-e third factor is
that more subjects in the TMD group probably take over-
doses of nutritional supplements, as confirmed by the
outcome from our investigation.
Parathyroid hormone (PTH) was significantly higher in
the TMD group of the present study. However, both elevated
and lowered levels of PTH were observed in the TMD
patient group on the individual level. A high level of PTH




















Figure 1: Flow chart of the study population: TMD patients and
healthy controls.
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hypoparathyroidism. Elevated levels of PTH in TMD pa-
tients compared to healthy controls have previously been
reported [6], where the majority of TMD patients had el-
evated PTH levels, primarily described as a response to low
vitamin D levels. -e level of PTH in depressed patients has
also been demonstrated to be significantly higher compared
to controls [23]. On the other hand, a clinical study ex-
amining hyperparathyroidism in patients with fibromyalgia,
widespread pain, and localized musculoskeletal pain con-
cluded there were no differences in prevalence between the
groups nor compared to the general population [24]. A few
patients in the present study also had elevated levels of free
thyroxine (FT4), which may reflect hyperthyroidism. A
recent clinical case-control study reported a significantly
higher prevalence of TMD symptoms as well as the severity
of symptoms in patients with Hashimoto thyroiditis (HT)
compared to healthy control subjects [25]. HTgoes through
several stages from hyperparathyroidism to hypoparathy-
roidism, and its main symptoms are like TMD, including
musculoskeletal pain and stiffness. -e fact that thyroid
hormones play an important role in muscle function [26] is
supported by the common occurrence of neuromuscular
symptoms [27] and musculoskeletal disorders [28] in pa-
tients with thyroid dysfunctions. -yroid disease has also
previously been associated with idiopathic tongue pain in a
clinical study [29]. Observed levels of PTH in the present
study may possibly reflect some prevalence of parathyroid
disturbances or disturbances in the hormonal thyroid-reg-
ulating pathways in the TMD group. However, there was no
overall significant difference in thyroid stimulating hormone
(TSH), nor in FT4, between the TMD patient group and the
control group. An exception was observed in the subgroup
of male TMD patients, who had significantly higher levels of
TSH compared to the subgroup of male controls.
Elevated PTH is often seen in association with low vi-
tamin D, leading to elevated calcium absorption from bone
[22]. Similarly, we observed a significant negative association
between PTH levels and vitamin D levels in the control
group but not in the patient group.-e observed association
may be explained by the fact that vitamin D levels were lower
in the control group, resulting in higher stimulation of
excretion of PTH, compared to the patient group. A sup-
porting observation from a laboratory database study, ex-
amining the association between serum PTH and vitamin D
levels in 19,172 subjects in the Israeli population, concluded
that vitamin D levels had to be below the reference value of
50 nmol/L to sufficiently elevate PTH levels [30]. A note-
worthy finding considering vitamin D and PTH levels in the
present study was that most subjects in both groups had
normal values of calcium. Elevated vitamin D and PTH in
the presence of normal calcium values were also observed in
a previous study of TMD patients [6]. A possible explanation
could be that normalized levels and intake of calcium may
suppress the increase of secretion of PTH, when vitamin D is
low [17].
-ere were no significant differences in CRP levels be-
tween the TMD group and the control group. Mean CRP
levels have previously been observed within the normal
range in patients with TMJD and were not affected by pain
[10]. -e fact that most TMD patients have normal values of
CRP means that the pain intensity is probably not directly
associated with inflammation. However, some patients in
Table 1: Serum analyses resulted in nineteen different determinants common in diagnostics. Second column shows normal values for
women and men at all ages. Most TMD patients and controls had values within normal biologic range. TMD patients had significantly
higher values of hemoglobin (p � 0.036), cobalamin (p � 0.023), albumin (p � 0.005), PTH (p � 0.038), and vitamin D (p � 0.005) and
significantly lower values of creatinine (p � 0.006) and potassium (p � 0.011) compared to controls.
Serum analyses Reference values
TMD Control p-value (paired
t-test)
Mean ±SD Range Mean ±SD Range (∗ � sign.)
Hemoglobin W: 11.7–15.3, M: 13.4–17.0 g/dL 14.1 1.28 8.1, 16.2 13.8 0.83 11.5, 16 0.036∗
EVF W: 0.35–0.46, M: 0.40–0.50 0.41 0.04 0.28, 0.48 0.41 0.02 0.35, 0.48 0.325
MCV 82–98 91.2 4.66 76, 102 90.1 3.62 83, 100 0.299
Homocysteine <15 umol/L 11.1 3.79 5.8, 28.0 11.3 3.03 5.7, 24.2 0.459
Transferrin R W: 1.9–4.4, M: 2.2–5.0mg/L 3.27 1.78 1.7, 14.6 2.98 0.80 1.7, 5.9 0.103
TSH 0.4–4.5mlE/L 1.63 0.83 0.01, 4.31 1.80 0.98 0.14, 4.72 0.191
FT4 9.5–22.0 pmol/L 16.0 3.13 7.8, 29 15.7 2.26 11.5, 27.0 0.266
Cobalamin 175–700 pmol/L 422 194.8 167, 1322 363 124.9 129, 702 0.023∗
Folate >8 nmol/L 20.7 10.41 7.7, 45.3 20.2 7.38 7.5, 45.3 0.450
CRP∗ (<1� 1) <5mg/L 2.43 3.09 1.0, 14.0 2.10 2.84 1.0, 20.0 0.268
Creatinine W: 45–90, M: 60–105 umol/L 65.6 10.47 45, 93 69.7 12.14 49, 108 0.006∗
Estimated GFR >90mL/min/l >60 — — >60 — — —
Sodium 137–145mmol/L 140.1 1.48 137, 144 140.0 1.39 136, 144 0.227
Potassium 3.5–5.0mmol/L 4.0 0.25 3.2, 4.6 4.1 0.31 3.4, 5.3 0.011∗
Calcium 2.20–2.55mmol/L 2.40 0.09 2.21, 2.63 2.40 0.08 2.15, 2.59 0.456
GT W: <40y� 10–45, >40y� 10–75U/L M:<40y� 10–80, >40y� 15–115U/L 22.2 19.63 8.0, 145.0 17.9 12.20 6.0, 72.0 0.078
Albumin <39y: 39–50, 40–69y: 39–48, >70y: 36–48 g/L 46.3 2.94 40.0, 53.0 45.1 1.96 40.0, 49.0 0.005∗
PTH 1.3–6.8 pmol/L 3.4 1.53 0.9, 8.2 2.9 1.09 1.0, 6.0 0.038∗
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the present study had elevated CRP levels ranging from 5 to
20mg/L that may potentially be enough to reflect a local
inflammation. In a radiographic CT and MRI study of pa-
tients with rheumatoid arthritis (RA), mean CRP levels were
between 10 and 20mg/L, and the levels of CRP were also
correlated with inflammation in the TMJ [9]. In other
studies of patients diagnosed with RA, higher levels of CRP
were correlated with resorbed condyles in the TMJ, seen on
CT [31], and low jaw opening capacity [32]. In a large
population of adults in the United States, elevated serum
CRP was positively associated with pain and headache when
assessed by questionnaires [33]. -e fact that low income
also was associated with pain and not with CRP indicates
that CRP levels contributed to increased pain independent of
pain-related social factors [33]. Albumin, which functions as
a carrier protein and has a role in maintaining colloid os-
motic pressure, was significantly higher in the TMD group.
Elevated levels of albumin normally reflect dehydration.
Moreover, high albumin levels have previously been asso-
ciated with metabolic syndrome [34]. -e fact that high
levels of albumin have previously been negatively associated
with pain [33] and significantly lower levels of inflammatory
cytokines in healthy older subjects [35] indicates that high
levels of albumin are not related to pain disorders. Since
albumin was high in our group of TMD patients, systemic
inflammation was also less likely.
Another indicator of high doses of nutritional supple-
mentation in our group of TMD patients was significantly
higher levels of cobalamin, possibly due to vitamin B12
supplementation. On the other hand, 10% of the TMD
patients had elevated levels of homocysteine, even though
there were no statistical differences in mean levels of
homocysteine compared to the control group. High
homocysteine levels reflect low levels of vitamin B12, vita-
min B6, and folate, and the observed elevated levels in some
patients may potentially be explained by the possibility of
reduced intake of diet sources in the patient group because of
jaw impairment and pain from chewing. However, there was
no statistical difference in serum folate levels between the
TMD patients and controls. A previous study of serum
analyses in TMD patients reported a high prevalence of low
vitamin B levels, including folate and vitamin B complex [7].
Similarly, a high prevalence of low vitamin B levels in pa-
tients with complex TMJ problems, including vitamin B1,
vitamin B6, vitamin B12, and folate, was shown in another
study [8].
In the TMD group, we observed some patients with
elevated levels of transferrin receptor (TfR) and low
Table 2: Gender-matched serum analyses: Results from serum analyses showed mean levels statistically differed between TMD patients and
controls, divided into subgroups of women and men. -e second column shows normal values for women and men at all ages. Significantly
higher levels of hemoglobin (p � 0.045), cobalamin (p � 0.020), albumin (p � 0.017), PTH (p � 0.040), and vitamin D (p � 0.002) were
observed in women in the TMD group. Significantly lower levels of creatinine (p � 0.018) and potassium (0.002) were observed in women in
the TMD group. Significantly higher levels of TSH (p � 0.040) and albumin (p � 0.026) were observed in men in the TMD group. -e
number of men was considerably smaller in both groups.
Gender-matched serum analyses Reference values
TMD (n� 60) Control (n� 60) p-value (paired t-test)
Mean ±SD Range Mean ±SD Range (∗ � sign.)
Hemoglobin
Women (n� 51 + 51) 11.7–15.3 g/dL 13.9 1.22 8.1, 15.7 13.6 0.70 11.5, 14.7 0.045∗
Men (n� 9 + 9) 13.4–17.0 g/dL 15.2 1.13 13.4, 16.2 14.9 0.62 14.0, 16.0 0.288
TSH
Women (n� 51 + 51) 0.4–4.5mlE/L 1.52 0.82 0.01, 4.31 1.80 1.04 0.14, 4.72 0.111
Men (n� 9 + 9) 0.4–4.5mlE/L 2.24 0.59 1.25, 3.34 1.84 0.52 1.17, 2.49 0.040∗
Cobalamin
Women (n� 51 + 51) 175–700 pmol/L 425 210.0 167, 1322 355 128.4 129, 702 0.020∗
Men (n� 9 + 9) 175–700 pmol/L 401 60.67 310, 455 403 100.3 291, 568 0.483
Creatinine
Women (n� 51 + 51) 45–90 umol/L 62.8 8.01 45, 81 66.2 8.77 49, 84 0.018∗
Men (n� 9 + 9) 60–105 umol/L 81.3 8.93 68, 93 88.9 9.97 74, 108 0.098
Potassium
Women (n� 51 + 51) 3.5–5.0mmol/L 4.0 0.25 3.2, 4.6 4.1 0.30 3.4, 5.3 0.002∗
Men (n� 9 + 9) 3.5–5.0mmol/L 4.1 0.21 3.9, 4.5 4.0 0.33 3.5, 4.5 0.267
Albumin




45.9 2.98 40.0, 53.0 44.9 1.91 40.0, 49.0 0.017∗
Men (n� 9 + 9) >70y: 36–48 g/L 48.0 2.08 45.0, 51.0 46.6 1.59 44.0, 48.0 0.026∗
PTH
Women (n� 51 + 51) 1.3–6.8 pmol/L 3.5 1.58 0.9, 8.2 2.9 1.03 1.0, 5.2 0.040∗
Men (n� 9 + 9) 1.3–6.8 pmol/L 2.7 1.10 1.1, 4.2 2.58 1.39 1.4, 6.0 0.385
Vitamin D
Women (n� 51 + 51) 50–113 nmol/L 75.3 26.23 19.0, 187.0 61.8 19.78 22.0, 127.0 0.002∗
Men (n� 9 + 9) 50–113 nmol/L 55.8 26.21 21.0, 111.0 57.6 11.02 42.0, 72.0 0.426
Pain Research and Management 5
erythrocyte volume fraction (EVF), which potentially could
indicate iron deciency or an increase in erythropoiesis
[36–38]. Iron deciencies have previously been observed in
TMD patients [7, 8]. Although, mean values of TfR and EVF
in the present study did not statistically dier between TMD
patients and controls, and the fact that hemoglobin was
signicantly higher in the TMD patient group supports the
explanation of higher erythropoiesis. Serum TfR has pre-
viously been observed to be elevated in children with
juvenile chronic arthritis, without any correlation to serum
transferrin or ferritin levels, indicating that serum TfR is an
inadequate indicator of iron levels in the presence of chronic
inammation [36].
e levels of creatinine were signicantly lower in the
TMD patient group. Creatinine is a degradation product
of creatine phosphate, which has an important role in
muscle function and fast energy production [39]. Low
levels of serum creatinine may reect muscle atrophy and
has also been directly associated to low bone mineral
density in subjects with normal renal function [40]. In a
randomized controlled trial of patients with bro-
myalgia, creatine supplementation resulted in signi-
cantly improved function of muscle; however, no
improvements in pain or psychosocial factors were ob-
served [41].
Potassium was signicantly lower in the TMD group.
Potassium homeostasis is regulated by renal and extra-
renal mechanisms, aected by acid-base balance and
hormonal regulation by epinephrine, insulin, and aldo-
sterone [42]. e uptake and release of extracellular
potassium is mainly mediated by the skeletal muscles
through several K+ channels [43], contributing to
maintain the extrarenal homeostasis. e fact that ab-
normal K+ channel activity has a role in chronic pain [44]
makes it reasonable to suspect that changes in potassium
homeostasis may aect the function of K+ channels in
painful disorders. Despite the presence of statistically
signicantly lower levels of potassium in our group of
TMD patients, the observed dierence probably has no
clinical value since most patients and controls had
Table 3: Elevated and lowered values: observed number and percent of patients and controls with elevated and lowered values of the
dierent determinants from the serum analyses. Mild to moderate vitamin D level deciency was seen in 11 TMD patients compared to 18
controls. Furthermore, we observed marginally elevated levels of CRP (n 7) and elevated levels of transferrin receptor (n 7) and
homocysteine (n 6), as well as lowered levels of erythrocyte volume fraction (EVF) (n 5), in the TMD group. FT4 was elevated in 3
patients and lowered in one patient, while parathyroid hormone (PTH) was elevated in 2 patients and lowered in 4 patients.
Elevated and lowered values
TMD Control
Elevated Lowered Elevated Lowered
n % n % n % n %
Hemoglobin 1 1.7 2 3.3 0 0.0 1 1.7
EVF 1 1.7 5 8.3 0 0.0 0 0.0
MCV 1 1.7 3 5.0 4 6.7 0 0.0
Homocysteine 6 10.0 0 0.0 3 5.0 0 0.0
Transferrin R 7 11.7 3 5.0 3 5.0 2 3.3
TSH 0 0.0 2 3.3 1 1.7 1 1.7
FT4 3 5.0 1 1.7 1 1.7 0 0.0
Cobalamin 5 8.3 1 1.7 1 1.7 1 1.7
Folate 0 0.0 2 3.3 0 0.0 1 1.7
CRP 7 11.7 0 0.0 4 6.7 0 0.0
Creatinine 0 0.0 0 0.0 1 1.7 0 0.0
Estimated GFR 0 0.0 0 0.0 0 0.0 0 0.0
Sodium 0 0.0 0 0.0 0 0.0 1 1.7
Potassium 0 0.0 1 1.7 1 1.7 1 1.7
Calcium 1 1.7 0 0.0 3 5.0 1 1.7
GT 2 3.3 5 8.3 0 0.0 7 11.7
Albumin 9 15.0 0 0.0 0 0.0 0 0.0
PTH 2 3.3 4 6.7 0 0.0 1 1.7

















Figure 2: Linear correlation between parathyroid hormone and
vitamin D in the TMD group (black) and the control group (grey).
Low levels of vitamin D were signicantly correlated (p  0.002)
with high levels of PTH in the control group; however, this cor-
relation was nonsignicant in the patient group.
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normal potassium levels. A possible explanation of lower
potassium levels in the patient group may be due to lower
intake of fluid or electrolyte status. However, sodium
levels were normal in all patients and did not statistically
differ from the control group, indicating normal elec-
trolyte balance.
-e prevalence and severity of TMD is higher in women
compared to men [1]. Results from a recent meta-analysis
showed that women had a two-time higher risk in devel-
opment of TMD [4]. In a clinical study of TMD patients,
women showed significantly higher pain intensity on the
VAS compared to men, as a respond to palpation of the
masticatory muscles as well as the TMJ [5]. Results from the
OPPERA study have shown that pain sensitivity, in the
majority of all pain measurements, is significantly higher in
women compared to men [45].
Because of the higher prevalence of TMD in women, we
found it interesting to reveal gender differences in the
serum analyses in both groups. -e gender-matched serum
analyses showed significantly higher levels of hemoglobin,
cobalamin, PTH, and vitamin D, as well as significantly
lower levels of creatine and potassium only in women in the
TMD group, compared to the control group. Albumin
levels were significantly higher in both men and women in
the TMD group, and TSH was significantly higher only in
men in the TMD patient group, compared to the control
group. -e results showed that most of the observed dif-
ferences in serum analyses, for both groups, were in the
subgroup of women. However, the observed gender dif-
ferences may be affected by the fact that men were a very
small population sample comprising only 9 subjects in each
group. More research must be carried out to fully examine
the possibility of an association between gender and serum
levels in TMD.
-e present study is one of the few studies on serum
analyses in TMD patients comparing levels in healthy
individuals. To our knowledge, this is the first study to use
as many as 19 different variables at the same time. Despite
a relatively small study sample, the results of our study may
contribute toward assessing and mapping risk factors and
characteristics of TMD. One limitation of the study was
the fact that the serum samples were taken at all seasons of
the year, while levels of some determinants, e.g., vitamin D
and PTH, may have some seasonal variability in the
Scandinavian countries. -e fact that there was some
geographical difference between the TMD patient group
and the control group may also have had an effect on the
results. -e possibility of cultural, diet-related, and so-
cioeconomic factors affecting serum levels of the presented
determinants in our study, as well as other similar reports,
should also be kept in mind. Another limitation is that
ultrasound was not used for diagnostics of TMD, which
has been tried but had too many obstacles to pass and
therefore was not used. -e gold standard for diagnostics
of TMJ disease is magnetic resonance imaging (MRI)
together with a clinical investigation for function and pain.
However, ultrasound for diagnostics has recently been
shown to be effective in the limb muscle and shoulders
[46, 47].
5. Conclusion
In the present study, no clear indication of systemic disease
or malnutrition in the TMD patient group was seen. -e
results from the serum analyses were mostly within normal
reference values, which resulted in rejection of our hy-
pothesis. All observed deficiencies in both groups were weak.
One of the most surprising results was that vitamin D levels
were lower in the control group compared to the TMD
group. Despite minor observed differences in TMD patients,
as compared with healthy subjects, we conclude that serum
analyses should be not be used as a biomarker of TMD nor as
a diagnostic tool for an individual subject with TMD. As an
outcome from our clinical investigation, we observed a small
group within the TMD group which likely took high doses of
vitamin supplements, which contributed to elevated serum
levels in some variables. Due to a relatively low number in
the study population, more research is warranted to clarify
the relationship between different serum determinants and
the etiology and maintenance of TMD.
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